Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,305.41 -2.72 (-0.05%) Dow
39,826.17 +19.40 (+0.05%) Nasdaq
16,754.21 -40.67 (-0.24%) Bitcoin USD
70,686.48 +3,614.69 (+5.39%) CMC Crypto 200
1,536.01 +47.47 (+3.19%)
Editas Medicine, Inc. (EDIT)
- GuruFocus.com
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
- GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical d
- Simply Wall St.
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its latest quarterly report and things are not looking great...
